Spirapril Production Cost Reports

The report provides detailed analysis essential for establishing a spirapril production plant. It encompasses all critical aspects necessary for spirapril production, including the cost of spirapril production, spirapril plant cost, spirapril production costs, and the overall spirapril production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a spirapril production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Spirapril Market Analysis: Demand and Supply Analysis, and Sourcing

Spirapril is a long-acting angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension. Chemically, it belongs to the enalapril family and shares the same side chain, but has an unusual replacement for proline. Instead of proline, it contains a spiro ring with two sulfur atoms, known as 1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid. Schering developed the drug under the codes Sch-33844 and TI-211-950 and launched it as Renormax. Sandoz marketed it as Renpress and Sandopril. In Germany, it remains available as Quadropril, with AWD.pharma holding the authorization and CT Arzneimittel co-marketing the product.

Demand is low, stable, and concentrated in a few regions. Spirapril never achieved widespread global adoption or sustained market presence. Its US approval covered 3, 6, 12, and 24 mg tablets, but FDA records now list all four strengths as discontinued. Europe retains a niche market, mainly in Germany and Russia, where one 6 mg tablet taken once daily remains in use. Spirapril's main advantage relates to its pharmacokinetics rather than clinical performance. Unlike most ACE inhibitors, it is cleared through both renal and fecal routes, so dosage adjustments are generally limited in moderate renal impairment. Its half-life is 24 hours or longer because its active metabolite binds tightly and remains bound.

The supply chain is unusually limited, narrow, and opaque for a small-molecule drug. There is no meaningful merchant market for its active pharmaceutical ingredient (API) with established pricing. Trade databases list no API suppliers, US drug master files, European certificates of suitability, or Japanese filings. The material used for the German product is manufactured within the marketing company's own supply chain, with little public information available. Research quantities are available from catalog suppliers such as MedChemExpress, while distributors including Parchem list spirapril and spirapril hydrochloride without manufacturing either product. A demand and supply analysis must consider prescription volumes in Germany and Russia, competition from lower-cost ACE inhibitors, and the lack of a second source. Upon receipt, buyers check assay, diastereomeric purity, related substances, water content, residual solvents, chloride content, and salt stoichiometry.

Summary of the Product, Grades, and Uses

Spirapril has the molecular formula C22H30N2O5S2 and a molar mass of 466.61 g/mol under CAS 83647-97-6. It is sold as the hydrochloride monohydrate under CAS 94841-17-5, as well as in anhydrous salt form with a molar mass of 503.07 g/mol. Its full chemical name is 8S-7-[2S-2-[[1S-1-ethoxycarbonyl-3-phenylpropyl]amino]-1-oxopropyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid. The molecule has three stereocenters, all of which must have the correct configuration, making synthesis particularly challenging. The base material is a white foam, while the hydrochloride is a white solid that melts with decomposition at around 192 to 194 degree Celsius.

Spirapril is a prodrug, which is an important consideration when setting product specifications. Liver esterases convert its ethyl ester into the diacid spiraprilat, coded Sch-33861 and registered under CAS 83602-05-5, with a molar mass of 438.56 g/mol. Only the diacid binds to and inhibits the enzyme. Oral bioavailability is approximately 40%, food has little effect on absorption, and peak activity occurs after two to three hours. API specifications cover identity testing by infrared spectroscopy and HPLC, assay, diastereomeric purity, related substances including the free diacid, water content measured by Karl Fischer titration, residual solvents, heavy metals, and chloride content.

The available grades are limited and consistent because the market is small. Pharmaceutical-grade hydrochloride monohydrate, manufactured to an in-house monograph, is the only commercial form. Reference standards, the spiraprilat metabolite, and labeled analogs are used for analytical testing and research.

Main End-Uses of Spirapril

Essential hypertension is by far the main use of spirapril. German prescribing information provides specific, cautious dosing guidelines with clear dose limits. Quadropril tablets contain 6.21 mg of spirapril hydrochloride monohydrate, equivalent to 6.0 mg of the hydrochloride. Treatment starts with half a tablet each morning. If blood pressure does not return to normal, the dose can be increased to one full tablet, but only after at least three weeks. This is the usual maintenance dose. Patients with creatinine clearance of 10 to 30 milliliters per minute start with half a tablet, while spirapril is not recommended for those with clearance below 10 milliliters per minute. Its suitability for patients with impaired renal function is a key reason prescribers choose it.

Chronic heart failure is the second use, although it is not an approved indication in every market. Its use in this condition is based on the established effects of ACE inhibitors and prescribing practices. ACE inhibitors reduce afterload, limit cardiac remodeling, and improve clinical outcomes. German reference sources describe spirapril as suitable for use across the stages of chronic heart failure. However, prescribing remains limited because enalapril, ramipril, lisinopril, and perindopril have much larger clinical outcome trial databases and lower costs.

Research and analytical applications form the third market. Demand is very small, irregular, and declining. Spirapril and spiraprilat are used as research compounds in studies of binding kinetics, prodrug activation, and structure-activity relationships. Chemists are also interested in the dithiolane spiro core as a constrained substitute for proline. Reference standards support analytical method development, impurity identification, and stability testing for the remaining commercial product.

Spirapril Market Risks

The main risk for spirapril is its position as a minor drug in a crowded, fully genericized class. Competition is widespread, inexpensive, and intense. Enalapril, ramipril, lisinopril, perindopril, and captopril are all affordable, widely available, and supported by extensive clinical outcome data, leaving little clinical justification for a new market entrant. The US market has already closed, with all strengths discontinued. European demand depends on a single product sold in only a few countries, meaning one decision by the authorization holder could end the market. There is no second API supplier to cover a supply shortfall, and none is expected to emerge.

Technical and regulatory challenges add to these commercial risks. Spirapril synthesis is costly, lengthy, complex, and sensitive to process conditions. Three stereocenters, a thioketal spiro ring, a protecting-group strategy, and an activated ester coupling step all increase the number of stages and reduce yields. The published synthesis route ends with size-exclusion chromatography, which is difficult to implement at commercial scale. Thiol reagents also create odor, corrosion, and waste-handling challenges that must be addressed in plant design. Regulatory challenges include the lack of a widely used monograph and a publicly available drug master file. A new supplier would need to develop its impurity and stability documentation from scratch. In processes of this type, rejected batches most commonly result from incorrect diastereomeric purity, excessive residual solvents, or free diacid levels above specification limits.

Spirapril Production Process and Main Cost Drivers

The spirapril production process runs from 4-keto-L-proline and the shared ACE inhibitor side chain through thioketal formation, deprotection, reductive amination, activated ester coupling, and salt formation.

1. By Thioketalisation of 4-Keto-Proline and Coupling to the Phenylpropyl Alanine Side Chain: The main inputs are 1-benzyloxycarbonyl-4-keto-L-proline, 1,2-ethanedithiol, boron trifluoride etherate, acetic acid, hydrogen bromide, L-alanine benzyl ester salt, ethyl 2-oxo-4-phenylbutanoate, a borohydride reducing agent, palladium on carbon, hydrogen, N-hydroxysuccinimide, a carbodiimide, triethylamine, dimethylformamide, acetonitrile, hydrochloric acid, and packaging.

The first step is to construct the ring, as the unusual spiro core defines the spirapril molecule. Production begins by converting the 4-keto group of a protected proline into a cyclic dithioketal. A Schering patent describes reacting 1-benzyloxycarbonyl-4-keto-S-proline with a slight excess of 1,2-ethanedithiol in acetic acid and ethyl acetate, using boron trifluoride etherate as a catalyst. The reaction runs for about four hours under nitrogen. The crude protected spiro acid is then recovered through bicarbonate extraction, acidification to pH 1, and ether extraction. An alternative method uses the methyl ester with p-toluenesulfonic acid in refluxing acetic acid.

Next, the amine is unmasked, and the side chain is built separately. The benzyloxycarbonyl group is cleaved with about 23 percent hydrogen bromide in acetic acid over roughly three hours. The product is precipitated with ether, then recrystallized from hot ethanol over charcoal, giving the spiro amino acid hydrobromide. The side chain is made in parallel by reductive amination, combining L-alanine benzyl ester p-toluenesulfonate with ethyl 2-oxo-4-phenylbutanoate in ethanol, then adding a cyanoborohydride. The product is purified as its hemimaleate, freed with bicarbonate, then hydrogenolysed over ten percent palladium on carbon, at about 60 psi. That removes the benzyl ester and leaves the ethyl ester untouched.

To finish, the two halves are joined, and the salt is made. The side-chain acid is activated as its N-hydroxysuccinimide ester using N-hydroxysuccinimide and a water-soluble carbodiimide in dry dimethylformamide over about twelve hours. That activated ester is added to the spiro amino acid hydrobromide in dimethylformamide at 0 to 5 degree Celsius. Two equivalents of triethylamine are added dropwise, then the mixture is stirred at room temperature for roughly sixteen hours. Workup adjusts to pH 4, extracts into ethyl acetate, and strips to a brown oil. The patent then purifies that by size-exclusion chromatography in methanol to a white foam. The hydrochloride is then crystallized using concentrated hydrochloric acid in acetonitrile. QC covers assay, diastereomers, related substances, water, residual solvents, and chloride. The main cost drivers are the protected keto-proline, the side chain intermediate, step count, and chromatography.

Main Factors Affecting Spirapril Production Cost

Spirapril production costs are driven mainly by the protected keto-proline intermediate. This material has no established volume market, regular stockists, or transparent pricing. 4-keto-L-proline is a specialized chiral intermediate produced from hydroxyproline or through other routes. Protecting it requires an additional step before the main chemistry begins. Since the dithiolane spiro acid has very few other applications, there is little production scale or competitive supply. Manufacturers must therefore produce this fragment themselves, commission its production, or operate without a reliable supply.

The side chain is the more economical part of the process in terms of volume, price, and availability. Large-scale production supports its supply and keeps costs competitive. Ethyl 2-oxo-4-phenylbutanoate and L-alanine esters are widely used commodity intermediates across the ACE inhibitor class, including enalapril, lisinopril, and other drugs produced in much larger volumes. Reductive amination using a borohydride is a routine process, and hydrogenolysis using palladium on carbon is a standard technique. Catalyst costs, hydrogen handling, and maleate purification add to expenses, but these are conventional manufacturing requirements.

The number of steps, purification requirements, and regulatory compliance complete the cost picture. Published synthesis routes involve multiple sequential steps, protecting groups, and yield losses. Thioketalization, deprotection, reductive amination, salt purification, hydrogenolysis, ester activation, coupling, chromatography, and salt formation require substantial processing. Yield losses accumulate across these steps, and chromatography must be replaced with crystallization for commercial-scale production. Thiol handling also requires odor-control systems, corrosion-resistant equipment, and dedicated waste treatment. Small production campaigns spread cleaning, changeover, validation, and analytical costs across very few kilograms, making these expenses a major contributor to the final delivered cost.

Raw Materials for Spirapril Production Plant and its Procurement

Raw material sourcing for spirapril splits into a scarce half and a commodity half. Scarcity sits in the proline fragment, start to finish, always. Protected 4-keto-L-proline comes from custom synthesis houses working from hydroxyproline or glutamate-derived routes, and 1,2-ethanedithiol comes from a small number of thiol producers. Ethyl 2-oxo-4-phenylbutanoate and L-alanine esters make up the commodity half, both widely traded for the whole class. Boron trifluoride etherate, hydrogen bromide in acetic acid, cyanoborohydride, palladium catalyst, N-hydroxysuccinimide, carbodiimide, triethylamine, dimethylformamide, acetonitrile, and drums complete the bill of materials.

The cheapest raw material is not always the cheapest route to on-spec spirapril. Keto-proline with partial racemization carries an unwanted diastereomer right through to the product. 1,2-ethanedithiol that has oxidized to disulfide gives incomplete thioketalisation and leaves keto starting material behind. Side chain made with poor stereocontrol in the reductive amination gives the wrong diastereomer at the benzylic center, which is hard to purge later. Wet dimethylformamide hydrolyses the activated ester, cuts coupling yield, and raises the free acid.

These sensitivities shape how a spirapril plant buys and qualifies its inputs. Contracts specify assay, enantiomeric and diastereomeric purity, water, and related substances for each chiral input. Vendor qualification runs through audits, certificates of analysis, and trial batches carried to final product. Incoming checks cover identity, assay by HPLC, chiral purity, and water by Karl Fischer. Because the proline fragment has a single-digit supplier list, a development agreement matters more than a purchase order. Locating the plant near a custom synthesis partner or an existing ACE inhibitor manufacturing facility reduces transportation costs, shortens lead times, and simplifies supplier qualification.

Sustainability and Regulatory Requirements

Spirapril manufacture raises environmental and occupational concerns that come mainly from the sulfur chemistry and the solvents. Thiol handling is the first problem, the loudest, and the hardest to permit. 1,2-ethanedithiol has an intense odor detectable far below harmful levels. Handling is closed, vented to scrubbers or carbon beds, and monitored, with spill procedures written around complaints as much as toxicity. Boron trifluoride etherate and hydrogen bromide in acetic acid are corrosive, and both need resistant equipment and scrubbed vents. Dimethylformamide is a reproductive toxicant under tightening restrictions and a candidate for substitution. Spent palladium catalyst is removed by filtration and sent for metal recovery. Solvents are recovered through distillation when their purity allows reuse, while sulfur-containing waste streams are sent for treatment.

Regulatory requirements depend on the limited availability of this product and the markets where it remains available. The finished drug has national authorizations in a few European markets, with Germany serving as the reference market. The API follows the authorization holder’s own specifications rather than a public monograph. A new US supplier would need to file a Type II drug master file and comply with FDA current Good Manufacturing Practice (cGMP) requirements under 21 CFR 210/211. The brand application in the United States has been discontinued. In Europe, an active substance master file or certificate of suitability would support supply, but neither is currently listed in public records. ICH Q7 governs API manufacturing, while Q3A and Q3C address impurities and solvents. Q6A covers specification setting, and M7 addresses genotoxicity assessments, which are particularly relevant given the reagents used.

CAPEX and OPEX for a Spirapril Production Plant

A spirapril plant is a small multipurpose API unit with thiol containment. Capital needs are moderate, manageable, and spread thin. Capital starts with glass-lined and alloy reactors sized in the hundreds of liters. They need low-temperature control for the coupling step, and corrosion resistance for boron trifluoride and hydrogen bromide. A dedicated thiol bay with closed charging, inert blanketing, vent scrubbing, and carbon adsorption is effectively mandatory. Hydrogenation needs a pressure vessel rated to a few bar, with catalyst filtration and nitrogen purging. Downstream come crystallizers, filters, centrifuges, rotary or thin-film evaporators, solvent recovery stills, and vacuum dryers. Replacing the chromatography with crystallization is the key development task, since preparative columns are costly at scale. Utilities cover steam, chilled brine, nitrogen, hydrogen, vacuum, and sulfur-capable effluent treatment. On the QC side, a laboratory houses chiral and achiral HPLC, LC-MS, headspace GC, and Karl Fischer titrators.

Spirapril operating costs are mainly driven by the protected keto-proline and side-chain intermediate, while thiol, reagents, catalysts, solvents, utilities, labor, quality control, waste treatment, packaging, and freight account for the remaining expenses. The cost per kilogram depends on the number of production steps, overall yield, diastereomeric control, and whether the final purification can be achieved through crystallization. Spirapril plant setup costs depend on batch size and whether the spiro fragment is manufactured in-house or purchased. In practice, production takes place in campaigns alongside other low-volume APIs, with reactors, solvent recovery systems, and utilities shared across products.

Plant Location and Investment Factors

A workable spirapril site is an existing small-volume API plant with chiral synthesis experience and a thiol handling capability already in place. Germany and Central Europe sit closest to the remaining demand, with AWD.pharma in Radebeul anchoring the finished product. India hosts deep ACE inhibitor intermediate capability, since enalapril and lisinopril chains have long been made there, and that overlaps directly with the spirapril side chain. China offers low-cost custom synthesis for the keto-proline fragment and the dithiol. The site needs permits for thiols, boron trifluoride, hydrogen, and solvent emissions.

For a spirapril project, the first step is to determine whether the production volume justifies the investment. The project is viable mainly as a toll-manufacturing or custom-supply arrangement linked to the existing finished product, or as part of a reference-standard portfolio. The next decision is how much of the production process to handle in-house. Purchasing the protected spiro acid simplifies production to coupling, workup, and crystallization, which a small facility can manage easily. Manufacturing it in-house captures more value but requires additional thioketalization and deprotection steps and generates more waste. A new entrant needs a committed offtake agreement, strict diastereomeric control, and a crystallization process that eliminates the need for chromatography.

Major Spirapril Producing Regions

Europe is where spirapril still lives, and Germany, specifically, is its center. AWD.pharma in Radebeul holds the German marketing authorization for Quadropril, with CT Arzneimittel co-marketing the tablets, and Russia remains a further market for the same product. Material flows inside that supply chain rather than through a merchant market, so there is no public production footprint to point at. The US was once a market through Schering's Renormax across four strengths, but all of them are discontinued. India and China host the custom synthesis capability any new route would rely on, for the keto-proline fragment, the dithiol, and the shared side chain. Research quantities come from catalog houses & distributors worldwide.

Key Spirapril Producers

AWD.pharma

• German pharmaceutical company in Radebeul holding the marketing authorization for Quadropril.
• Supplies spirapril hydrochloride monohydrate tablets at 6 mg for essential hypertension.
• Competes on the molecule's renal and fecal dual elimination and once-daily dosing.
• Serves German prescribers, with the product also reaching Russia and neighboring markets.

CT Arzneimittel

• German generic and specialty pharmaceutical company co-marketing Quadropril.
• Distributes the spirapril tablets alongside a broad cardiovascular portfolio.
• Competes on pharmacy distribution reach and price positioning.
• Serves German pharmacies and prescribers.

Sandoz

• Swiss generics company that marketed spirapril as Renpress and Sandopril.
• Carried the product in several European markets during its commercial period.
• Competed on generic cardiovascular breadth and European reach.
• Now focused on higher-volume ACE inhibitors within the same class.

Schering

• US pharmaceutical company that discovered spirapril under the codes Sch-33844 and Sch-33861.
• Held the US application for Renormax tablets at 3, 6, 12 & 24 mg.
• Competed on being first with a dual-eliminated, long-acting ACE inhibitor.
• All US strengths are now listed as discontinued.

Parchem

• US chemical distributor listing both spirapril and its hydrochloride.
• Supplies small quantities with documentation for research and development use.
• Competes on sourcing hard-to-find materials and small pack sizes.
• Serves laboratories, formulators, and specialty buyers.

MedChemExpress

• Life science supplier cataloging spirapril hydrochloride as a research chemical.
• Provides batch certificates of analysis for analytical and biological work.
• Competes on availability of discontinued and niche molecules.
• Serves academic and pharmaceutical research groups.